According to a new study, there’s a high chance you’ll become infected with HIV in the coming months.
The study, published in the journal JAMA Internal Medicine, found that about 2% of Americans will be infected by mid-December, with an additional 2% likely to catch the virus in late December.
That means the number of Americans who are likely to become infected in the near future will be more than double the 1% of people who were infected during the last three years.
Researchers believe that a high proportion of infected people have already been exposed to other infectious agents and are not yet at high risk.
The study also found that 1 in 4 people who are infected with the virus will contract the disease in their lifetime.
Researchers say that even though many of these people are at high-risk for contracting HIV, they may have missed a critical opportunity to test for the virus and avoid the disease.
“Our findings suggest that even with limited exposure, many individuals who are at risk of HIV infection are not fully aware of the risk,” said study co-author Dr. Steven W. Smith, a professor of epidemiology at Emory University School of Medicine.
“These individuals may not have been exposed at the highest levels to HIV, but may have not been tested and may be at higher risk for catching the virus.”
The study involved 1,532 individuals in the United States, Australia, New Zealand, Canada and the United Kingdom.
They were divided into three groups based on their likelihood of catching the disease, how likely they were to catch it, and whether they were tested.
Each person was randomly assigned to one of three groups.
In the first group, they were randomly assigned either to receive an injection of the drug known as Truvada, or a placebo.
In the second group, participants received a placebo injection, but were told they would receive a shot of the HIV vaccine, called PrEP.
In a third group, the participants received PrEP and were also told they could receive an HIV vaccine shot.
In all three groups, participants were given daily injections of Truvadera and PrEP for six months.
Each injection was delivered by a nurse practitioner, and the participants were monitored for a minimum of two weeks afterward.
As part of the study, researchers also monitored the health of all participants over the course of the six-month study.
During the study period, participants in the three groups who were not tested and did not receive PrEP were still monitored for signs of infection, such as fever, sore throat or loss of appetite.
In order to determine the likelihood of getting HIV in their lifetimes, the researchers used data from the National Center for Health Statistics’ annual National Survey of Family Growth, a long-term survey of people ages 15 and older.
Researchers found that among people in the study who were tested and who had HIV, the odds of being infected were approximately twice the odds for people in groups who did not get tested.
However, the study also showed that among the people who did get tested and were not HIV positive, the risk of becoming infected increased by only about 0.8% when the HIV test was used to determine who would be tested for HIV.
“These findings suggest the existence of a significant under-reporting of HIV infections among those who are HIV-positive, but also suggest that the HIV-negative population may have been under-reported,” Smith said.
“While we still do not have a fully developed and accurate diagnostic test, we are confident that the PrEP vaccine will reduce the likelihood that someone will be exposed to the virus for the rest of their life.”
This study was funded by the National Institute of Allergy and Infectious Diseases.
For more news on HIV, see our HIV news page.